Company intelligence / Profile preview

HCT Regenerative

Tamsui, New Taipei City, Taiwan

Ownership: Private
Employees: ~35
Development stage: Other

Overview

HCT Regenerative is a leader in tissue engineering and cell therapy in Taiwan, operating the region's only AATB-accredited tissue bank. The company has successfully commercialized tissue-based products like AmnioGen and is currently advancing autologous cell therapies HCT-1 and HCT-2 through clinical trials for hair follicle and cartilage regeneration, showing promising safety and efficacy profiles in early-stage studies.

Therapeutic areas: OphthalmologyRheumatologyDermatology
Modalities: Cell therapyStem cell therapyBiologicInduced pluripotent stem cell derived therapyTissue engineering
Industry: Biotech

Drug pipeline

1 asset

AMNIOAID

Unknown

Partnerships

National Taiwan UniversityNational Health Research Institutes (NHRI)

Beyond the preview

Go deeper on HCT Regenerative.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCT Regenerative.

Explore the full profile